Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07203066

Effects of Oxaliplatin-Induced Peripheral Neuropathy on Hand Function, Grip Strength and Quality of Life in Colorectal Cancer Patients

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
84 (estimated)
Sponsor
Fenerbahce University · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to investigate the effects of oxaliplatin-induced peripheral neuropathy on hand function, grip strength, and quality of life in colorectal cancer patients. Assessing the motor symptoms of CIPN and sharing the results in clinical settings will help guide evidence-based practices and interventions.

Detailed description

Oxaliplatin is a chemotherapy drug frequently used in the treatment of colorectal cancers, the third most common type of cancer. However, oxaliplatin is associated with long-term neurotoxicity, the most common dose-limiting side effect. Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of platinum-based chemotherapy agents, such as oxaliplatin. CIPN limits patients' ability to tolerate treatment and adversely affects long-term quality of life and physical functionality. In individuals undergoing colorectal cancer treatment, the prevalence of CIPN has been reported as 58% at 6 months, 45% at 12 months, 32% at 24 months, and 24% at 36 months post-treatment. Additionally, oxaliplatin exhibits a "coasting phenomenon," in which CIPN symptoms continue to worsen for approximately 3 months after treatment. Although the incidence and sensory symptoms of oxaliplatin-induced CIPN during chemotherapy have been well documented, the chronic-phase motor symptom burden of oxaliplatin-induced CIPN has not been reported. Studies investigating the motor aspects of CIPN are insufficient, and further research is needed to determine its prevalence, progression, and impact on functional outcomes.

Conditions

Interventions

TypeNameDescription
OTHERobservational onlyobservational only

Timeline

Start date
2025-09-24
Primary completion
2025-12-24
Completion
2026-02-24
First posted
2025-10-02
Last updated
2025-10-02

Source: ClinicalTrials.gov record NCT07203066. Inclusion in this directory is not an endorsement.